Lucid Genomics

Lucid Genomics is a Munich-based bioinformatics spin-off providing a sophisticated, AI-driven software platform for the secondary and tertiary analysis of long-read sequencing data. The company's core technology addresses the significant challenge of interpreting the 'dark genome'—complex structural variants and non-coding regions—by integrating multi-omics data and 3D genome architecture to improve detection accuracy and variant prioritization. It is positioned as a technology-agnostic analysis layer, serving leading academic and clinical institutions to accelerate genomic research and diagnostics. While currently focused on the research and diagnostic tools market, its platform has clear applications in supporting therapeutic target discovery and clinical trial matching.

AI-powered software platform for secondary/tertiary analysis of long-read sequencing data. Integrates multi-omics (RNA-seq, methylation, epigenetics, Hi-C) and 3D genome architecture to detect, prioritize, and interpret structural variants and repeat expansions across coding and non-coding regions.

Competes in a crowded bioinformatics space against open-source consortia and commercial vendors like Fabric Genomics, Sophia Genetics, and DNAnexus. Key differentiation lies in its specialized focus on long-read data, integration of 3D genome architecture, and claimed superior AI-driven accuracy for structural variant detection in the 'dark genome'.